Nausea and vomiting are among the most distressing adverse effects of cancer chemotherapy. They can lead to both physical and psychological complications if uncontrolled. The exact mechanism for chemotherapy-induced nausea and vomiting is not known; it is thought to occur through numerous neuronal pathways acting on different sites. Chemotherapy-induced nausea and vomiting are broken down into 3 phases: acute, delayed, and anticipatory. The incidence of each phase depends largely on the chemotherapy agent used and is primarily treated with different antiemetic agents. Pharmacists can assist in optimizing antiemetic use by selecting appropriate antiemetics based on the emetogenicity of the cancer treatment and helping to individualize therapy to each patient’s specific needs.
Berger AM, Clark-Snow RA. Adverse effects of treatment. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott-Raven; 1997:2705-2714.
2.
Rizk AN, Hesketh PJ. Antiemetics for cancer chemotherapy-induced nausea and vomiting. Drugs R&D. 1999;2:229-235.
3.
Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Cancer. 1995;76:343-356.
4.
Valley A.Gastrointestinal complications of cancer chemotherapy. In: Finley RS, Balmer C, eds. Concepts in Oncology Therapeutics. Bethesda, MD: American Society of Health-System Pharmacists; 1998;148-166.
5.
Taylor AT, Holland EG. Nausea and vomiting. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach. 3rd ed.Stamford, CT: Appleton &Lange; 1997;751-765.
6.
Ettinger DS. Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis. Sem Oncol. 1995; 22(4 suppl 10):6-18.
7.
Aapro MS. Review of experience with ondansetron and granisetron. Ann Oncol. 1993;4:S9-S14.
8.
Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3:1379-1384.
9.
Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs. 1996;52:639-648.
10.
Roila F, Boschetti E, Tonato M, et al. Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol Cancer Clin Trials. 1994;14:238-242.
11.
Jacobsen PB, Redd WH. The development and management of chemotherapy-related anticipatory nausea and vomiting. Cancer Invest. 1988;6:329-336.
12.
Morrow GR. Clinical characteristics associated with the development of anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment. J Clin Oncol. 1984;2: 1170-1176.
13.
Alba E, Bastus R, de Andres L, et al. Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology. 1989;46:26-30.
14.
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
15.
Reece PA, Stafford I, Abbott RL, et al. Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol. 1989;7:270-275.
16.
ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharmacy. 1999;56:729-764.
17.
Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329:1790-1796.
18.
Veyrat-Follet C, Farinotti R, Palmer JL. Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs. 1997; 53:206-234.
19.
Kris MG, Tyson LB, Gralla RJ, et al. Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med. 1983;309:433-434.
20.
Glodstein D, Levi JA, Woods RL, et al. Double-blind randomized cross-over trial of dexamethasone and prochlorperazine as anti-emetics for cancer chemotherapy. Oncology. 1989;46:105-108.
21.
Carr BI, Blayney DW, Goldberg DA, et al. High doses of prochlorperazine for cisplatin-induced emesis. Cancer. 1987;60:2165-2169.
22.
Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol. 1984;2:782-787.
23.
Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7:108-114.
24.
Tortorice PV, O’Connell MB. Management of chemotherapy-induced nausea and vomiting. Pharmacotherapy. 1990;10:129-145.
25.
Pomeroy M, Fennelly JJ, Towers M.Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986;17:285-288.
26.
McCabe M, Smith FP, Macdonald JS, et al. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6:243-246.
27.
Hainsworth J, Harvey W, Pendergrass K, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol. 1991;9:721-728.
28.
Warr D, Wilan A, Venner P, et al. A randomized, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. Eur J Cancer. 1993;29A(1):33-36.
29.
Chevallier B.Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer. 1990;26(suppl 1):S33-S36.
30.
Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994; 12:596-600.
31.
Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995;332(1):1-5.
32.
Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med. 1999;340:190-195.
33.
Ladabaum U, Hasler WL. Novel approaches to the treatment of nausea and vomiting. Dig Dis. 1999;17:125-132.
34.
Hesketh PJ, Gralla RJ, Webb RT, et al. Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol. 1999;17:338-343.
35.
Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
36.
Jantunen IT, Kataja VV, Muhonen TT. An overview of randomized studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer. 1997;33(1):66-74.
37.
Pater JL, Lofter WS, Zee B, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997;8:181-185.
38.
Morrow GR, Morrell C.Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med. 1982;307:1476-1480.
39.
Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol. 1993;11:1384-1390.
